Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Bifidobacterium bifidum + Bifidobacterium longum + Bifidobacterium longum infantis + Lacticaseibacillus casei + Lactobacillus acidophilus + Lactococcus lactis & Type 2 diabetes (T2D)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

XXX - Bifidobacterium bifidum + Bifidobacterium longum + Bifidobacterium longum infantis + Lacticaseibacillus casei + Lactobacillus acidophilus + Lactococcus lactis & Type 2 diabetes (T2D)

This randomized, double-blind, parallel-group, controlled clinical trial revealed that Probiotics modestly improved HbA1c (in the intention-to-treat (ITT) analysis, these changes were not significant) and fasting insulin in people with type 2 diabetes (1).

References

(1) Firouzi et al. 2017 Eur J Nutr 56(4): 1535-1550

see also:
Probiotics (living agents) & Type 2 Diabetes (T2D)
[Type 2 diabetes (T2D) & Drugs/Treatments](brai…

References (Sources)

Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial
Firouzi et al. 2017 Eur J Nutr 56(4): 1535-1550

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!